Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‘JAK-pot’ collaboration

BACKGROUND: JAK-inhibitors (JAKi), recently approved in rheumatoid arthritis (RA), have changed the landscape of treatment choices. We aimed to compare the effectiveness of four current second-line therapies of RA with different modes of action, since JAKi approval, in an international collaboration...

Descripción completa

Detalles Bibliográficos
Autores principales: Lauper, Kim, Iudici, Michele, Mongin, Denis, Bergstra, Sytske Anne, Choquette, Denis, Codreanu, Catalin, Cordtz, René, De Cock, Diederik, Dreyer, Lene, Elkayam, Ori, Hauge, Ellen-Margrethe, Huschek, Doreen, Hyrich, Kimme L, Iannone, Florenzo, Inanc, Nevsun, Kearsley-Fleet, Lianne, Kristianslund, Eirik Klami, Kvien, Tore K, Leeb, Burkhard F, Lukina, Galina, Nordström, Dan C, Pavelka, Karel, Pombo-Suarez, Manuel, Rotar, Ziga, Santos, Maria Jose, Strangfeld, Anja, Verschueren, Patrick, Courvoisier, Delphine Sophie, Finckh, Axel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9484385/
https://www.ncbi.nlm.nih.gov/pubmed/35705376
http://dx.doi.org/10.1136/annrheumdis-2022-222586

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9484385/
https://www.ncbi.nlm.nih.gov/pubmed/35705376
http://dx.doi.org/10.1136/annrheumdis-2022-222586

Ejemplares similares